Literature DB >> 8365543

Identification of annexin II, annexin VI and glyceraldehyde-3-phosphate dehydrogenase as calcyclin-binding proteins in bovine heart.

F Y Zeng1, V Gerke, H J Gabius.   

Abstract

1. Matrix-immobilized calcyclin as affinity ligand in chromatography led to purification of three protein bands at 68, 36 and 35 kDa from bovine heart that required Ca2+ for binding. 2. Polyacrylamide-immobilized phosphatidylserine separated this fraction into a phospholipid-binding part (68 kDa, 35 kDa), also attaching to phospholipid vesicles even in the presence of calcyclin, and a flow-through part, constituting approx 30% of the total fraction (36 kDa). 3. Enzyme assays and electrophoretic mobility showed an at least close relationship of the 36 kDa band to glyceraldehyde-3-phosphate dehydrogenase. Interaction between enzyme and calcyclin in a solid-phase assay was inhibited by sialoglycoproteins and depended strongly on the integrity of carboxyl and hydrophobic groups of the enzyme. The interaction between the two proteins had a KD value of 110 nM. 4. Application of annexin-specific antibodies revealed an immunological relationship of the 35 and 68 kDa calcyclin-binding proteins to members of the annexin family, namely to annexin II (35 kDa) and annexin VI (68 kDa). The N-terminal amino acid sequence of a cleavage peptide of the 68 kDa protein was identical to a sequence stretch in human annexin VI, corroborating this evidence.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8365543     DOI: 10.1016/0020-711x(93)90116-v

Source DB:  PubMed          Journal:  Int J Biochem        ISSN: 0020-711X


  15 in total

1.  1H NMR assignments of apo calcyclin and comparative structural analysis with calbindin D9k and S100 beta.

Authors:  B C Potts; G Carlström; K Okazaki; H Hidaka; W J Chazin
Journal:  Protein Sci       Date:  1996-11       Impact factor: 6.725

2.  Differentially expressed genes of human microvascular endothelial cells in response to anti-dengue virus NS1 antibodies by suppression subtractive hybridization.

Authors:  Yue Yin; Lan Jiang; Danyun Fang; Lifang Jiang; Junmei Zhou
Journal:  Viral Immunol       Date:  2013-05-22       Impact factor: 2.257

3.  Design of high-affinity S100-target hybrid proteins.

Authors:  Atoosa Rezvanpour; Jeremy M Phillips; Gary S Shaw
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

Review 4.  Calcium-dependent and -independent interactions of the S100 protein family.

Authors:  Liliana Santamaria-Kisiel; Anne C Rintala-Dempsey; Gary S Shaw
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

5.  High resolution solution structure of apo calcyclin and structural variations in the S100 family of calcium-binding proteins.

Authors:  L Mäler; B C Potts; W J Chazin
Journal:  J Biomol NMR       Date:  1999-03       Impact factor: 2.835

6.  p30, a novel protein target of mouse calcyclin (S100A6).

Authors:  A Filipek; U Wojda
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

7.  Dentin phosphoprotein binds annexin 2 and is involved in calcium transport in rat kidney ureteric bud cells.

Authors:  Keith Alvares; Paula H Stern; Arthur Veis
Journal:  J Biol Chem       Date:  2013-03-22       Impact factor: 5.157

8.  Ca2+ concentration during binding determines the manner in which annexin V binds to membranes.

Authors:  P J Trotter; M A Orchard; J H Walker
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

9.  Merging carbohydrate chemistry with lectin histochemistry to study inhibition of lectin binding by glycoclusters in the natural tissue context.

Authors:  Sabine André; Herbert Kaltner; Klaus Kayser; Paul V Murphy; Hans-Joachim Gabius
Journal:  Histochem Cell Biol       Date:  2015-11-09       Impact factor: 4.304

10.  S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility.

Authors:  T Nedjadi; N Kitteringham; F Campbell; R E Jenkins; B K Park; P Navarro; F Ashcroft; A Tepikin; J P Neoptolemos; E Costello
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.